EN DE
Watch SyntekaBio Inc for free: we tell you when fair value or trend changes.
Data-driven stock valuation

SyntekaBio Inc (226330) fair value: what the stock is really worth

As of Oct 28, 2026: fair value (intrinsic value) of SyntekaBio Inc stock KRW 94, price KRW 1,074, upside -91.3%, quality 36 out of 100. Rating: strongly overvalued. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.

  1. Fair value 30%+ above price?No
  2. Quality 50+?No
  3. In an uptrend?No
  4. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare KR · ISIN KR7226330009

SI SyntekaBio Inc logo Thin data Oct 26, 2026

SyntekaBio Inc

226330 · KQ

Weakest SetupStrongly overvalued and low quality.

Our calculation puts a fair price 91% below what the stock costs today.

Low debt
Expensive Growth (revenue 5y +41.3 %/yr in KRW)
Fair value 93.72 KRW · Strongly overvalued (−91.3%)
Quality 36/100
Negative free cash flow
Trails peers (3/8)
Narrow moat 12/100
Thin data
⚠ Dilution
Watch SyntekaBio Inc for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

16,970 KRW 1,009 KRW Fair Value 93.72 KRW Jun 2021 Oct 2026

White line = price, green steps = our fair value per fiscal year. As of Oct 26, 2026.

How to read this chart

60‑month range 1,009 KRW – 16,970 KRW · fair‑value band 61.86 KRW – 117.15 KRW · the 1,074 KRW price screens above the 93.72 KRW fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Oct 26, 2026.

Follow SyntekaBio in your weekly email

Every Wednesday you see whether SyntekaBio is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

SyntekaBio, Inc. operates as an artificial intelligence new drug development company based on genomic big data primarily in South Korea. It derives new drug candidates using DeepMatcher, an AI drug development platform that combines new drug development technology and genomic big data technology.

Show moreShow less

The company also researches and develops biomarker detection for individual cancer drug screening, disease susceptibility, immune typing, pharmacogenomic typing, and multi-omics information-based drug side effect prediction technology.

The company was founded in 2009 and is headquartered in Daejeon, South Korea.

Stock analysis

SyntekaBio Inc (226330) currently trades at 1,074 KRW, while our model-based Fair Value estimate is 93.72 KRW, 91.3% below the price, so the stock looks overvalued today.

Show more

Valuation

How firm this estimate is: it rests on 1 models at a data quality of 95/100, which puts the data coverage at low.

Scenario range: 61.86 KRW (bear) to 117.15 KRW (bull), the price of 1,074 KRW sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 36/100 (below-average quality), in the Healthcare sector.

Expensive Growth: The company is growing, but growth may require heavy reinvestment or weak cash conversion.

SyntekaBio Inc reported revenue of 3.4B KRW in FY2025 versus 317M KRW in FY2021, a compound +81.4%/yr. Reported net income was −17.4B KRW in FY2025.

Key figures

Market cap 26.1B KRW (≈ $19.5M) Micro · P/S ratio 9.95 · Return on equity −60.0% · Return on assets (EBIT) −23.0% · Operating margin −484% · Revenue (TTM) 3.1B KRW · Revenue growth (YoY) +29.9% · Free cash flow −10.7B KRW.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 12 out of 100 (medium confidence).

What moves the price

The share trades about 82% below its 52-week high and 6% above its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at 4% fair-value upside, at −91%, 226330 screens richer than that median.

Fair Value models

Bear 61.86 KRW Fair Value 93.72 KRW Bull 117.15 KRW
Price 1,074 KRW · Upside -91.3%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds. Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Best data coverage
NCAV (Graham) 72.77 KRW 110.26 KRW 137.82 KRW 54
All 1 models by family
Asset-Based
NCAV (Graham) 72.77 KRW 110.26 KRW 137.82 KRW 54

The fair value above starts from this blend and is adjusted for dilution from new shares.

Open the full fair value analysis →

Quality Score breakdown

Overall quality 36/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 3
How much profit the company makes from its sales and capital
Quality Growth 67
Are margins and returns getting better?
Cashflow 3
Do the profits arrive as real cash?
Financial strength 72
Debt, balance sheet and risk of trouble
Investment 99
Does it invest with discipline instead of growing at any price?
Low Volatility 50
How calm the share price moves, does not count
Momentum 8
Price trend of the last 3 to 12 months, does not count
Near the 52-week high 1
Distance to the 52-week high, does not count
New shares 0
Buys back shares or issues new ones?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 44/100
The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Revenue growth 1 year
+2,736.7%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+141.3%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+41.3%
Start year 2020 (pandemic)
Revenue growth 8 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+72.6%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−1,164.2% (2020) → −313.9% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

226330 screens overvalued: fair value 91% below the price. Compare with Veeva Systems Inc →

Compare SyntekaBio Inc with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Health Information Services · 121 stocks

Beats the industry median on 2/6 measures
Overall it trails its industry peers.
Valuation
Quality Score 36 · Bottom 25%
Fair Value upside −91.3% · Bottom 25%
Profitability
Return on assets −37.3% · Bottom 25%
Growth and dividend
Revenue growth (quarter YoY) 29.9% · Top 25%

Valuation Multiplesvs Health Information Services median · lower = cheaper

P/B 0.82× · Cheapest 25%
P/S (12 months) 8.44× · Priciest 25%

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)0 · sector 0
FUTURE (revenue growth)100 · sector 40
PAST (return on equity)0 · sector 11
HEALTH (low debt)100 · sector 98
DIVIDEND (yield)0 · sector 36

VALUE 0: the price sits above our fair-value range.

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Health Information Services stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Veeva Systems Inc VEEV $318.18 $350.00 +10% vs 226330
HealthEquity, Inc HQY $103.97 $114.37 +10% vs 226330
Doximity, Inc DOCS $33.39 $36.73 +10% vs 226330
Inventurus Knowledge Solutions Limited IKS ₹1,703 ₹1,873 +10% vs 226330
Waystar Holding WAY $28.02 $29.10 +4% vs 226330
Hinge Health, Inc HNGE $113.90 $51.25 −55% vs 226330
BrightSpring Health Services, Inc BTSG $58.36 $25.86 −56% vs 226330
Pro Medicus Limited PME A$196.00 A$85.12 −57% vs 226330
XtalPi Holdings 2228 HK$6.05 HK$1.53 −75% vs 226330
Privia Health Group PRVA $22.16 $5.52 −75% vs 226330

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names ⭐ Top Rated 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Peter Lynch Fair Value Formula &…Calculator with industry benchmark
Run the numbers yourself: free valuation calculators
DCF CalculatorP/E Ratio CalculatorPEG Ratio CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorIntrinsic ValueIntrinsic vs Extrinsic ValueP/E Ratio by Sector
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

SyntekaBio Inc · Fair Value
93.72 KRW −91%Fair Value
Calculator →

Cite: Fair Value Calculator (2026). "SyntekaBio Inc Fair Value". https://www.fairvalue-calculator.com/stock/226330

Frequently asked questions

Is SyntekaBio Inc (226330) overvalued or undervalued?
As of Oct 26, 2026, our model estimates a fair value of 93.72 KRW versus a price of 1,074 KRW, about −91% upside (overvalued).
What is the fair value of 226330?
Our model-based fair value for SyntekaBio Inc is 93.72 KRW (as of Oct 26, 2026), built from audited fundamentals. The current price: 1,074 KRW.
What is the quality score of 226330?
SyntekaBio Inc has a Quality Score of 36/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for SyntekaBio Inc (226330)?
Our model-based price target is the fair value of 93.72 KRW (as of Oct 26, 2026) from 1 valuation models. Cautious scenario 61.86 KRW, optimistic scenario 117.15 KRW. It is a calculation from audited fundamentals, not an analyst target.
What is the SyntekaBio Inc stock forecast for 2026?
Our models put fair value at 93.72 KRW, about −91% upside versus a price of 1,074 KRW (overvalued). Cautious scenario 61.86 KRW, optimistic scenario 117.15 KRW. The calculation is refreshed regularly with new filings.
What is the revenue of SyntekaBio Inc (226330)?
SyntekaBio Inc reported trailing-twelve-month revenue of about 3.1B KRW (latest available figure, as of Oct 26, 2026).
What is the intrinsic value of SyntekaBio Inc (226330)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For SyntekaBio Inc it is 93.72 KRW per share (as of Oct 26, 2026), against a price of 1,074 KRW. It is the blended result of 1 valuation models (cash flow, earnings, asset, dividend).
Is SyntekaBio Inc stock overvalued or undervalued in 2026?
As of Oct 26, 2026, 226330 trades above its calculated fair value: price 1,074 KRW, fair value 93.72 KRW, a gap of about −91% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 226330?
No. The price is what the market pays today (1,074 KRW); the fair value is what the company's own numbers justify (93.72 KRW). For SyntekaBio Inc the two are 980.28 KRW per share apart. That gap is exactly why we show both numbers side by side.
How much is SyntekaBio Inc worth?
The market values SyntekaBio Inc at about 26.1B KRW (market capitalisation, as of Oct 26, 2026). Per share that is 1,074 KRW; our models calculate a fair value of 93.72 KRW per share.
What do the bullish and bearish scenarios say about 226330?
Our models span a range for SyntekaBio Inc: cautious scenario 61.86 KRW, base 93.72 KRW, optimistic 117.15 KRW per share (as of Oct 26, 2026, price 1,074 KRW). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of SyntekaBio Inc (226330)?
Balance-sheet figures for SyntekaBio Inc (as of Oct 26, 2026): return on equity −60.0%. They feed the Quality Score of 36/100, which measures business quality independently of the share price.
How far is 226330 from its 52-week high?
SyntekaBio Inc trades at 1,074 KRW, about 82% below its 52-week high of 5,900 KRW and 6% above the low of 1,009 KRW (as of Oct 28, 2026). Distance from the high says nothing about value: that is what the fair value of 93.72 KRW is for.
Which stocks are comparable to SyntekaBio Inc?
From the same area (Healthcare) we also value Veeva Systems Inc, Pro Medicus Limited, BrightSpring Health Services, Inc, Hinge Health, Inc, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is SyntekaBio Inc stock attractive at the current price?
The data as of Oct 26, 2026: price 1,074 KRW, calculated fair value 93.72 KRW (−91%), Quality Score 36/100, from 1 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 226330 calculated?
We run SyntekaBio Inc through 1 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of 93.72 KRW, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.4 % above its aggregate fair value. SyntekaBio Inc itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of SyntekaBio Inc (226330)?
The closing price on Oct 28, 2026 was 1,074 KRW. Our model-based fair value is 93.72 KRW, about −91% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with SyntekaBio Inc right now?
The price sits above even our optimistic bull case (117.15 KRW). The favourable scenario is already priced in. Weak quality (36/100) and above fair value at the same time, the margin of safety is missing on both counts. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. A fairly wide model range (61.86 KRW to 117.15 KRW) leaves room in how you read the outcome.

Key figures of SyntekaBio Inc

How large is the market capitalisation of SyntekaBio Inc (226330)?
The market capitalisation of SyntekaBio Inc is 26.1B KRW (≈ $19.5M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of SyntekaBio Inc (226330)?
The price-to-sales ratio of SyntekaBio Inc is 9.95 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What is the return on equity of SyntekaBio Inc (226330)?
The return on equity (ROE) of SyntekaBio Inc is −60.0% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of SyntekaBio Inc (226330)?
On an EBIT basis the return on assets of SyntekaBio Inc is −23.0% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of SyntekaBio Inc (226330)?
The operating margin of SyntekaBio Inc is −484% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at SyntekaBio Inc (226330)?
Revenue at SyntekaBio Inc is growing +29.9% versus a year earlier (3y avg +141%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much free cash flow does SyntekaBio Inc (226330) generate?
The free cash flow of SyntekaBio Inc is −10.7B KRW (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
Free · no account needed

Watch SyntekaBio Inc in the live analysis

One click puts SyntekaBio Inc on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 28,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.